Vectura Appoints James Ward-Lilley as CEO
Vectura Group has announced the appointment of James Ward-Lilley as CEO and Executive Director. James will succeed Dr Chris Blackwell who, as previously announced, leaves Vectura at the end of June 2015.
James joins the Group on 1 October 2015 from AstraZeneca where he is currently Vice President Respiratory, Inflammation & Autoimmunity, GPPS ("Global Product and Portfolio Strategy"). In his current role James has responsibility for the development of AstraZeneca's RIA ("Respiratory, Inflammation and Autoimmunity") strategy which has included the recent acquisitions of Almirall's respiratory business and Pearl Therapeutics.
Prior to this, James led the AstraZeneca Investor Relations team from 2011 to 2012.
James has had an extensive career at AstraZeneca, spanning 28 years across a variety of commercially focused roles. James progressed from sales and marketing roles in the UK through to Country Head of Belgium and Luxembourg a position he held between 2002 and 2005. He then led AstraZeneca's business in China to become the number one pharmaceutical company in the market in 2008. James went on to become Regional Vice President for Central Eastern Europe and the Middle East where the business enjoyed a period of strong growth with sales doubling to $2billion during his tenure.
James is a BA Hons graduate, has an MBA and holds the Institute of Marketing Diploma.
The Board confirms that as previously announced, Dr Trevor Phillips will act as Interim CEO from the end of June 2015 until James Ward-Lilley joins the company as CEO.
Bruno Angelici, Chairman, commented: "We are delighted that James is joining as CEO. His significant relevant experience in the respiratory market which he has gained within a major global pharmaceutical company will be a considerable asset for Vectura. James joins at an exciting and important time for Vectura and we are confident that the company will continue to grow from strength to strength under his leadership."
James Ward-Lilley commented: "I am delighted to have accepted the role of CEO of Vectura and to build on the already strong foundations that are in place. I am looking forward to driving the business forward and ensuring the company achieves its goal on becoming a speciality pharmaceutical company."
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance